Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132087 | 0.79 | HSD11B1 (0.69) | HSD11B1NPSR1HPGDKDM4EMEN1 | |
| SCHEMBL13544829 | 0.73 | HSD11B1 (0.61) | HSD11B1NPSR1HPGDKDM4EMEN1 | |
| SCHEMBL3620374 | 0.73 | HSD11B1 (0.61) | HSD11B1NPSR1HPGDKDM4EMEN1 | |
| SCHEMBL21884192 | 0.71 | HSD11B1 (0.58) | HSD11B1SMYD3NPSR1HPGDKDM4E | |
| SCHEMBL23518575 | 0.69 | HSD11B1 (0.54) | HSD11B1NPSR1HPGDMEN1ALDH1A1 | |
| SCHEMBL1515374 | 0.69 | HSD11B1 (0.54) | HSD11B1NPSR1HPGDMEN1ALDH1A1 | |
| SCHEMBL23518502 | 0.69 | HSD11B1 (0.54) | HSD11B1NPSR1HPGDMEN1ALDH1A1 | |
| SCHEMBL3623689 | 0.67 | HSD11B1 (0.61) | HSD11B1EPHX2 | |
| SCHEMBL5327904 | 0.66 | ALDH1A1 (0.56) | HSD11B1NPSR1HPGDALDH1A1CYP2C19 | |
| SCHEMBL3623686 | 0.66 | HSD11B1 (1.00) | HSD11B1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | claimed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | claimed |
| EP-2094263-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2009-09-02 | — | — | EP | claimed |
| WO-2008074384-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2008-06-26 | — | — | WO | claimed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | claimed |
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2094263-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074384-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, CYP11B1 | HSD11B1 1/4885SMYD3 3534/4885NPSR1 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.